Talk:Colestyramine

WikiProject class rating
This article was automatically assessed because at least one WikiProject had rated the article as start, and the rating on other projects was brought up to start class. BetacommandBot 16:25, 10 November 2007 (UTC)

Requested move 15 June 2016

 * The following is a closed discussion of a requested move. Please do not modify it. Subsequent comments should be made in a new section on the talk page. Editors desiring to contest the closing decision should consider a move review. No further edits should be made to this section. 

The result of the move request was: Moved by Quercus solaris. (non-admin closure) — Andy W.  ( talk  · ctb) 23:27, 17 June 2016 (UTC)

Cholestyramine → Colestyramine – Recommended international nonproprietary name of the drug. Whynie 483 (talk) 16:18, 15 June 2016 (UTC)


 * Support. In my view Wikipedia should have a standard of using the international nonproprietary name (INN) for all pharmaceutical drug article titles unless there is a specific reason not to. A reason that is sensible and documented on the talk page. And "I'm from the US or UK so I'm more used to the USAN or BAN" is not a valid reason in and of itself. You can have the article clearly show what the USAN and BAN are without it necessarily being the article title. I also maintain that every drug article should explicitly indicate what the USAN, BAN, JAN, and AAN are. If they are the same as the INN, then fine, indicate that however is sensible, like maybe "USAN = INN". But don't fail to answer the question. Quercus solaris (talk) 01:23, 16 June 2016 (UTC)


 * Support per Naming_conventions_(chemistry). Plantdrew (talk) 16:57, 16 June 2016 (UTC)


 * Thank you, Plantdrew, for supplying that link, which shows that this is already the WP guideline (which I had not known). Accordingly, I moved the page. Quercus solaris (talk) 22:14, 17 June 2016 (UTC)


 * The above discussion is preserved as an archive of a requested move. Please do not modify it. Subsequent comments should be made in a new section on this talk page or in a move review. No further edits should be made to this section.